Martin Reck, MD, PhD, on Monotherapy vs Combination Treatment for High PD-L1–Expressing NSCLC: Expert Perspective

Posted: Monday, January 1, 0001

Martin Reck, MD, PhD, of the LungenClinic, discusses the clinical implications of the KEYNOTE-598 findings on combining pembrolizumab with ipilimumab vs pembrolizumab alone to treat patients who have high PD-L1–expressing non–small cell lung cancer.